NEW YORK (GenomeWeb) – Nuclea Biotechnologies said today that it is partnering with the Institut de recherches cliniques de Montréal (IRCM) to validate mass spec assays for insulin, proinsulin, and c-peptide.

Under the partnership the two companies will run the assays on clinical sample cohorts at both Nuclea and IRCM's facilities to test the precision, sensitivity, and reproducibility of the assays.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.